AI Portfolio Summary
In 2025 Q4, Rosalind Advisors, Inc. maintained a portfolio of 48 distinct positions. The most significant new addition to the portfolio was REPLIMUNE GROUP INC, which now represents 4.82% of the total fund value. They heavily accumulated shares in FENNEC PHARMACEUTICA, increasing their position by 25.8%. Conversely, Rosalind Advisors, Inc. completely exited their position in REZOLUTE INC.
Total Positions
48
Quarter
2025 Q4
Top Holding
DCTH (11.6%)
Top 10 Concentration
60.7%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
1-25 of 48
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
DCTH
DELCATH SYSTEMS...
|
Healthcare | 11.60% | 11.28% |
#1
Prev: #1
|
7.0 | no change | no change |
P
S
|
3,300,389 | $33,003,890 | 2023 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
SVRA
SAVARA INC
|
Healthcare | 7.21% | 4.88% |
#2
5
Prev: #7
|
4.9 | -596,279 | -14.9% |
P
S
|
3,403,721 | $20,524,438 | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
FENC
FENNEC PHARMACE...
|
Healthcare | 7.07% | 6.64% |
#3
Prev: #3
|
6.3 | 536,668 | 25.8% |
P
S
|
2,613,508 | $20,124,012 | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
XERS
XERIS BIOPHARMA...
|
Healthcare | 5.83% | 5.00% |
#4
2
Prev: #6
|
4.8 | 315,934 | 17.6% |
P
S
|
2,111,700 | $16,576,845 | 2023 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
VRDN
VIRIDIAN THERAP...
|
Healthcare | 4.92% | 4.43% |
#5
4
Prev: #9
|
2.5 | -150,000 | -25.0% |
P
S
|
450,000 | $14,004,000 | 2023 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
MDWD
MEDIWOUND LTD
|
Healthcare | 4.86% | 4.61% |
#6
2
Prev: #8
|
2.9 | no change | no change |
P
S
|
749,054 | $13,827,537 | 2023 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
VSTM
VERASTEM INC
|
Healthcare | 4.85% | 5.82% |
#7
3
Prev: #4
|
2.4 | -141,088 | -7.3% |
P
S
|
1,788,475 | $13,807,027 | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
REPL
REPLIMUNE GROUP...
|
Healthcare | 4.82% | — |
#8
Prev: #—
|
5.4 | 1,410,497 | no change |
NEW
|
1,410,497 | $13,710,031 | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ATYR
ASTRIA THERAPEU...
|
Healthcare | 4.78% | 2.59% |
#9
9
Prev: #18
|
2.9 | no change | no change |
P
S
|
1,039,080 | $13,601,557 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CYBN
CYBIN INC
|
Healthcare | 4.77% | 3.02% |
#10
6
Prev: #16
|
3.9 | 157,540 | 10.5% |
P
S
|
1,657,540 | $13,558,677 | 2024 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
EYPT
EYEPOINT PHARMA...
|
Healthcare | 4.43% | 3.16% |
#11
3
Prev: #14
|
3.8 | 40,000 | 6.2% |
P
S
|
690,000 | $12,606,300 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CGON
CG ONCOLOGY INC
|
Healthcare | 4.38% | 4.13% |
#12
2
Prev: #10
|
2.8 | no change | no change |
P
S
|
300,000 | $12,456,000 | 2025 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CYTK
CYTOKINETICS IN...
|
Healthcare | 4.36% | 7.51% |
#13
11
Prev: #2
|
1.7 | -204,955 | -51.2% |
P
S
|
195,045 | $12,393,159 | 2025 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
XFOR
X4 PHARMACEUTIC...
|
Healthcare | 3.66% | 1.81% |
#14
6
Prev: #20
|
4.5 | 1,061,313 | 68.7% |
P
S
|
2,605,920 | $10,423,680 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
MNMD
MIND MEDICINE M...
|
Healthcare | 3.53% | 3.02% |
#15
Prev: #15
|
2.4 | no change | no change |
P
S
|
750,000 | $10,042,500 | 2025 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
PROF
PROFOUND MEDICA...
|
Healthcare | 2.96% | 1.16% |
#16
8
Prev: #24
|
4.2 | 376,770 | 54.4% |
P
S
|
1,068,955 | $8,412,676 | 2023 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
NSPR
INSPIREMD INC
|
Healthcare | 2.44% | 3.22% |
#17
4
Prev: #13
|
2.0 | no change | no change |
P
S
|
3,905,743 | $6,952,222 | 2023 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
OCUL
Ocular Therapeu...
|
Healthcare | 1.71% | 1.60% |
#18
3
Prev: #21
|
1.7 | no change | no change |
P
S
|
400,000 | $4,856,000 | 2024 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
AVBP
ARRIVENT BIOPHA...
|
Healthcare | 1.53% | — |
#19
Prev: #—
|
4.1 | 215,871 | no change |
NEW
|
215,871 | $4,343,325 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
TLPH
TALPHERA INC
|
Healthcare | 1.43% | 1.34% |
#20
3
Prev: #23
|
1.1 | -806,484 | -18.4% |
P
S
|
3,579,273 | $4,080,371 | 2023 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
MYO
MYOMO INC
|
Healthcare | 1.23% | 1.16% |
#21
4
Prev: #25
|
1.0 | 48,984 | 1.3% |
P
S
|
3,839,772 | $3,494,193 | 2023 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
N/A
PUT
INVESCO QQQ TR
|
—
|
PUT Option | 1.06% | 0.53% |
#22
5
Prev: #27
|
3.4 | 200,000 | 80.0% |
P
S
|
450,000 | $3,028,500 | — | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | ||
|
PYPD
POLYPID LTD
|
Healthcare | 1.06% | 1.05% |
#23
3
Prev: #26
|
0.4 | -222,112 | -24.2% |
P
S
|
696,556 | $3,023,053 | 2024 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
OKUR
ONKURE THERAPEU...
|
Healthcare | 0.74% | — |
#24
Prev: #—
|
3.8 | 730,488 | no change |
NEW
|
730,488 | $2,118,415 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
N/A
PUT
SPDR S&P 500 ET...
|
—
|
PUT Option | 0.66% | 0.25% |
#25
9
Prev: #34
|
3.3 | 210,000 | 70.0% |
P
S
|
510,000 | $1,886,100 | — | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | ||
|
RZLT
REZOLUTE INC
|
Healthcare | 0.00% | 5.81% |
Sold All 😨
(Was: #5) |
0.0 | -1,807,202 | -100.0% |
CLOSED
|
— | $— | 2024 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
VRNA
VERONA PHARMA P...
|
Unknown | 0.00% | 3.65% |
Sold All 😨
(Was: #11) |
0.0 | -100,000 | -100.0% |
CLOSED
|
— | $— | 2023 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
IDYA
IDEAYA BIOSCIEN...
|
Healthcare | 0.00% | 3.26% |
Sold All 😨
(Was: #12) |
0.0 | -350,000 | -100.0% |
CLOSED
|
— | $— | 2025 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
QURE
UNIQURE NV
|
Healthcare | 0.00% | 2.49% |
Sold All 😨
(Was: #19) |
0.0 | -125,000 | -100.0% |
CLOSED
|
— | $— | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
N/A
PUT
ATYR PHARMA INC
|
—
|
PUT Option | 0.00% | 1.53% |
Sold All 😨
(Was: #22) |
0.0 | -1,570,200 | -100.0% |
CLOSED
|
— | $— | — | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | ||
|
ATXS
ASTRIA THERAPEU...
|
Healthcare | 0.00% | 0.38% |
Sold All 😨
(Was: #29) |
0.0 | -1,542,520 | -100.0% |
CLOSED
|
— | $— | 2023 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
N/A
CALL
REZOLUTE INC
|
—
|
CALL Option | 0.00% | 0.19% |
Sold All 😨
(Was: #35) |
0.0 | -263,100 | -100.0% |
CLOSED
|
— | $— | — | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | ||
|
N/A
CALL
IDEAYA BIOSCIEN...
|
—
|
CALL Option | 0.00% | 0.08% |
Sold All 😨
(Was: #36) |
0.0 | -35,900 | -100.0% |
CLOSED
|
— | $— | — | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | ||
|
N/A
PUT
SCHOLAR ROCK HL...
|
—
|
PUT Option | 0.00% | 0.00% |
Sold All 😨
(Was: #39) |
0.0 | -100,000 | -100.0% |
CLOSED
|
— | $— | — | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) |
Showing 1-25 of 48 holdings